RxDoctor Payments DataLook up a doctor →

Mohammad Rafieetary

Optometry · Memphis, TNNPI 1750384541

Payments from drug & device makers

$167,384in general payments, 2019–2025

Across 384 payments — averaging $435.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optos, Inc.$54K
  • Apellis Pharmaceuticals, Inc.$45K
  • Astellas Pharma US Inc$27K
  • Regeneron Healthcare Solutions, Inc.$16K
  • Regeneron$4K
  • Genentech USA, Inc.$4K
  • plus $17K from 33 others
$8,305in research payments, 2019–2025

Across 3 payments — averaging $2768.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$6K
  • Regeneron$2K

What the payments were for

  • Consulting fees$44,36027%
  • Speaking & faculty fees$87,30153%
  • Travel & lodging$22,50614%
  • Food & beverage$9,6456%
  • Education$1910%
  • Entertainment$2,2421%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167,384 in reported general payments places this provider in the 95th percentile of 34 optometry providers in Tennessee.

See all optometry providers in Tennessee

Medicare billing

Part B allowed, 2024
$297,810
Medicare patients
1,093
Services billed
4,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost24$11,145
CombiganBrimonidine Tartrate/Timolol25$10,048
Brimonidine Tartrate157$9,272
Prednisolone Acetate135$6,339
Latanoprost175$1,771
Timolol Maleate111$1,298
Ketorolac Tromethamine35$1,294
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat59$1,087
Dorzolamide Hcl42$919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$629$21,19349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 34 optometry providers in Tennessee.

Other optometry in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →